Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Cingulate Inc. (CINGW)

    Price:

    0.05 USD

    ( + 0.00 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    CINGW
    Name
    Cingulate Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    0.048
    Market Cap
    326.196k
    Enterprise value
    11.681M
    Currency
    USD
    Ceo
    Shane J. Schaffer
    Full Time Employees
    13
    Ipo Date
    2021-12-08
    City
    Kansas City
    Address
    1901 West 47th Place

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    BioNTech SE

    VALUE SCORE:

    6

    Symbol
    BNTX
    Market Cap
    22.626B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    3.694B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.624B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -1.625
    P/S
    0
    P/B
    10.319
    Debt/Equity
    1.318
    EV/FCF
    -1.977
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -0.616
    Debt/assets
    0.435
    FUNDAMENTALS
    Net debt/ebidta
    0.072
    Interest coverage
    0
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.012
    Capex to revenue
    0
    Capex to depreciation
    0.353
    Return on tangible assets
    -2.098
    Debt to market cap
    0.124
    Piotroski Score
    1.000
    FUNDAMENTALS
    PEG
    -0.187
    P/CF
    -1.942
    P/FCF
    -1.982
    RoA %
    -209.760
    RoIC %
    -255.329
    Gross Profit Margin %
    0
    Quick Ratio
    1.264
    Current Ratio
    1.264
    Net Profit Margin %
    0
    Net-Net
    -0.168
    FUNDAMENTALS PER SHARE
    FCF per share
    -3.302
    Revenue per share
    0
    Net income per share
    -4.063
    Operating cash flow per share
    -3.264
    Free cash flow per share
    -3.302
    Cash per share
    1.127
    Book value per share
    0.640
    Tangible book value per share
    0.640
    Shareholders equity per share
    0.640
    Interest debt per share
    0.843
    TECHNICAL
    52 weeks high
    0.051
    52 weeks low
    0.038
    Current trading session High
    0.048
    Current trading session Low
    0.038
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.792
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.058
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.229
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.131
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    -0.0436205%
    P/E
    -0.135
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.659
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.340
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.081
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.743
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.763
    DESCRIPTION

    Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.

    NEWS